BioCryst Pharmaceuticals raised its full year 2026 total revenue guidance to a range of US$715 million to US$730 million, alongside reporting third quarter revenue of US$180.29 million, net income of ...
Source LinkBioCryst Pharmaceuticals raised its full year 2026 total revenue guidance to a range of US$715 million to US$730 million, alongside reporting third quarter revenue of US$180.29 million, net income of ...
Source Link
Comments